The occurrence of mental health symptoms in isotretinoin‐treated adolescents
Pediatric Dermatology · 2024
DOI: 10.1111/pde.15595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Dermatology, 2024. Verfasst von Keith Miller und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Isotretinoin, Acne Vulgaris, Dermatologic Agents, Mental Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NCATS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Isotretinoin treatment for acne can reduce adverse psychiatric outcomes in adults, but there has been little investigation of the incidence of psychiatric outcomes in treated adolescents.
Methods
This retrospective cohort study using the Rochester Epidemiology Project identified 606 patients aged 12–18 prescribed isotretinoin over a 10‐year period between January 1, 2008 and December 31, 2017. Medical records were reviewed to identify psychiatric diagnoses before and during isotretinoin therapy, as well as psychiatric symptoms not captured by formal diagnoses and changes to isotretinoin dosing because of psychiatric diagnoses or symptoms.
Results
One hundred seventy‐seven (29.2%) had a psychiatric diagnosis prior to isotretinoin initiation, but 98 (16.2%) had a new psychiatric diagnosis or psychiatric symptom while taking isotretinoin. Patients with a psychiatric history were no more likely than those without to receive a new psychiatric diagnosis during treatment (4.5% vs. 3.7%; p = .650), but did experience more psychiatric symptoms, primarily low mood and mood swings (23.7% vs. 7.7%; p < .001). Only 25.5% of the 98 with a new psychiatric diagnosis or psychiatric symptom had a subsequent dose change. A dose change was more likely if patients received a new psychiatric diagnosis (41.7% vs. 20.3%; p = .037) or patients did not have a psychosocial explanation for psychiatric symptoms (34.4% vs. 10.8%; p = .009).
Conclusions
A substantial proportion of adolescent patients prescribed isotretinoin had a prior psychiatric diagnosis. This predicts more psychiatric symptoms during isotretinoin treatment. Adolescents with a psychiatric history who have worsening symptoms and those with new‐onset psychiatric symptoms would benefit from close monitoring while taking isotretinoin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA.
- Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Keith Miller, Jonathan G Leung
Förderung
- NIA NIH HHS
- NCATS NIH HHS
- NIH HHS
- National Institutes of Health
- National Institute on Aging
- National Center for Advancing Translational Sciences
Zitieren
APA
Miller, K., McKean, A., Hand, J., Rackley, S., Leung, J. G., LeMahieu, A., Geske, J., & Bostwick, J. M. (2024). The occurrence of mental health symptoms in isotretinoin‐treated adolescents. Pediatric Dermatology. https://doi.org/10.1111/pde.15595
Vancouver
Miller K, McKean A, Hand J, Rackley S, Leung JG, LeMahieu A, et al. The occurrence of mental health symptoms in isotretinoin‐treated adolescents. Pediatric Dermatology. 2024. doi:10.1111/pde.15595
BibTeX
@article{Miller2024,
author = {Miller, Keith and McKean, Alastair and Hand, Jennifer and Rackley, Sandra and Leung, Jonathan G and LeMahieu, Allison and Geske, Jennifer and Bostwick, J Michael},
title = {The occurrence of mental health symptoms in isotretinoin‐treated adolescents},
journal = {Pediatric Dermatology},
year = {2024},
doi = {10.1111/pde.15595}
}
EUVIMED